 |
|
|
| |
Association of Sex and Race with Health-related Quality of Life in Patients Treated with Darunavir/ritonavir-based Therapy in the GRACE (Gender, Race And Clinical Experience) Trial
|
| |
| |
Presented at the 1st Intl Workshop on Women & HIV
Reorted by jules Levin
Judith Feinberg, MD1, Michael Saag, MD2, Judith Currier, MD, MSc3, Kathleen Squires, MD4, Robert Ryan, MS5, Joseph Mrus, MD, MSc6
1University of Cincinnati College of Medicine, Cincinnati, OH, USA; 2University of Alabama at Birmingham, Birmingham, AL, USA; 3University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA; 4Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA; 5Tibotec Inc, Titusville, NJ, USA; 6Tibotec Therapeutics, Titusville, NJ, USA
"the largest improvements in total FAHI scores were seen in women and black patients, despite the fact that these two groups had both lower virologic response rates and higher discontinuation rates compared with men and with Hispanic and white patients, respectively"
|
| |
|
|
|
|
|
